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Juvenile idiopathic arthritis reflects a group of clinically heterogeneous arthritides hallmarked
by elevated concentrations of circulating immune complexes. In this study, the circulating
immune complex proteome was examined to elucidate disease-associated proteins that are
overexpressed in patients with an aggressive, and at times destructive, disease phenotype. To
solve this proteome, circulating immune complexes were isolated from the sera of patients
with chronic, erosive or early-onset, aggressive disease and from patients in medical remis-
sion or healthy controls subsequent to protein separation by 2-DE. Thirty-seven protein spots
were overexpressed in the circulating immune complexes of the aggressive disease groups as
compared to controls, 28 of which have been confidently identified to date. Proteolytic frag-
ments of glyceraldehyde-3-phosphate dehydrogenase, serotransferrin, and a-1-antitrypsin
have been identified among others. In total, these 28 putative disease-associated proteins
most definitely contribute to immune complex formation and likely have a significant role in
disease etiology and pathogenesis. Moreover, these proteins represent markers of aggressive
disease, which could aid in diagnosis and management strategies, and potential therapeutic
targets to prevent or control disease outcome. This is the first in-depth analysis of the
circulating immune complex proteome in juvenile idiopathic arthritis.
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1 Introduction
Juvenile idiopathic arthritis (JIA) describes a clinically
heterogeneous group of arthritides which begin before 16
years of age, persist for more than six weeks, and are of
unknown etiology [1–3]. Several disease subtypes comprise
JIA, each having distinct methods of presentation, clinical
signs and symptoms, and genetic backgrounds (for certain
subtypes). Of the seven disease subtypes, rheumatoid factor-
positive (RF1) polyarthritis has the greatest risk for poor
disease outcome [4, 5] and least favorable spontaneous
remission rates [6]. Moreover, this JIA subtype is char-
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acterized by progressive and diffuse joint involvement with
early changes such as joint space narrowing, decrease in
carpal length, ankylosis, erosions, and subluxation. Severe
deforming arthritis is commonly observed five years from
onset [7].
Even though the etiology and pathogenesis of JIA are
unclear, a role for elevated concentrations of pathogenic
circulating immune complexes (CICs) has been clearly
established [3, 8–17]. The formation of transient CICs
represents a normal physiological response to an antigen,
but persistent, elevated concentrations of CICs result in
defective removal and subsequent tissue deposition [18].
Several attempts have been made to identify proteins in
CICs from both adult rheumatoid arthritis (RA) and JIA
patients by various methods; however, protein identities
were inconclusive and based on molecular weight infor-
mation alone [8, 19]. Moreover, only a limited number of
approaches were used to characterize CICs for potential
antigens/antibodies; the most common method being
immunoprecipitation followed by SDS-PAGE and immu-
noblotting (for review see references [8, 19–27]). The lack of
an effective method for efficient CIC isolation and the
relatively low concentrations of antigen in CICs contribute
to the difficulties in their identification. Recent attempts to
identify disease-associated proteins have been restricted to
the analysis of whole biologic fluid; for example, serum,
synovial fluid (SF), urine, and cerebrospinal fluid [28–34].
However, analysis of these fluids pose limitations to study-
ing disease-associated proteins because of the wide dynamic
range of proteins and abundance of common proteins in
complex biological samples. These limitations, in part,
explain the inability to discover low abundance serum
proteins [35–37]. A more focused approach would be to
deconstruct CICs as the key contributors to pathology. The
characterization of CICs, in addition to whole fluid, could
potentially corroborate findings or resolve issues regarding a
disease-associated protein’s role in the disease process.
Moreover, CIC analysis may provide differential expression
patterns of disease-specific proteins and key posttransla-
tional modification(s) that elicit the initial autoimmune
response by reducing the dynamic range of high abundance
proteins and increasing the sensitivity of detection [38]. To
purify CICs from biological fluids, in relatively large
amounts, and further study the differentially expressed
proteins by MS analysis would significantly enhance our
ability to identify disease markers. The development of such
processes would also identify posttranslational modifica-
tions that are fundamental to disease pathogenicity. The
formation of CICs represents early immune responses and
hence directly contributes to disease pathogenesis in JIA.
Therefore, proteomic analysis of CICs would yield more
insight into the disease process.
With the advent of modern proteomic methods, namely
2-DE coupled with MS, the opportunity to characterize
complex protein profiles has made identifying disease-
associated proteins a reality. While 2-DE and LC MS/MS
are not well-suited for high-throughput screening, they are
ideal methods for deconstructing complex protein mixtures
like CICs in search of disease-associated proteins and
potential autoantigens [39]. In this study, we use a novel
CIC isolation technique, 2-DE, and nanoflow HPLC-MS/MS
to identify disease-associated proteins in CICs isolated
from patients with an unremitting and erosive phenotype
of RF1 polyarticular JIA. These proteins represent markers
of aggressive disease and potential therapeutic targets to
prevent or control disease outcome. This report is the
first detailed analysis of a CIC proteome from patients
with JIA.
Table 1. Clinical and demographic characteristics of the study subjects
Disease subtype CE EOA MR Healthy
Total number 3 5 6 4
Age (years) 22.572 14.675.6 17.275.7 22.473.4
Male/female (n) 0/3 0/5 0/6 0/4
Disease duration (years) 10.973.8 1.371.3 77 7.4 n/a
Swollen joint count (n) 19.377.6 20.876.4 7.378.6 0
Tender joint count (n) 4.376.7 11.876.9 0.370.5 0
Erosions/JSN (n) 3/3 1/1 2/3 0/0
CRP (mg/dL) 2.772.8 2.572 0.370.2 n/a
ESR (mm/h) 90734.8 36726.1 8.874.4 n/a
RF (P/N) 3/0 5/0 6/0 0/4
Anti-CCP (P/N) 3/0 3/2 2/4 0/4
DMARD (yes/no) 3/0 0/5 6/0 0/4
NSAID (yes/no) 3/0 0/5 6/0 0/4
Biologic (yes/no) 3/0 0/5 3/3 0/4
Values are the mean (7standard deviation) or the number of subjects. n/a, not applicable or not determined; JSN, joint space narrowing;
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; anti-CCP, anti-CCP antibodies; DMARD, disease
modifying antirheumatic drug; NSAID, nonsteroidal antiinflammatory drug; P, positive; N, negative.
830 J. M. Low et al. Proteomics Clin. Appl. 2009, 3, 829–840
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
2 Materials and methods
2.1 Patient and serum samples
Patient and healthy donor sera were collected from the
outpatient clinics of the Saint Louis University Medical
Center and Cardinal Glennon Children’s Hospital in Saint
Louis, Missouri. A total of eight JIA sera were collected from
patients with RF1 polyarthritis according to ACR criteria [3],
three with chronic, erosive (CE) and five with an early onset,
aggressive (EOA) phenotype (Table 1). In addition, we
evaluated six RF1 polyarticular JIA patients in medical
remission (MR), and four age- and sex-matched healthy
controls. Patients in MR were defined as being asympto-
matic with no active synovitis and normalized inflammatory
mediators. Healthy controls were defined as having normal
laboratory values and no clinical evidence of disease. Serum
samples were aliquoted and stored at 801C until isolation
of CICs by affinity chromatography. The study was approved
by the Institutional Review Board of the Saint Louis
University Medical Center.
2.2 Isolation of CICs
Prior to affinity chromatography, serum samples were
thawed and kept in a 371C water bath for 10min followed by
centrifugation at 7000 g for 10min. CICs from the clear
serum supernatant were adsorbed by passing 3mL of serum
diluted with 1:1 with 1PBS over 2mL of ProceptorTM-
conjugated 4B-FF sepharose resin (ProGen Biologics,
Wildwood, MO) [40]. After sample adsorption, the resin
was washed with five column volumes of 1PBS
followed by one column volume of 500mM NaCl solution
to remove any nonspecifically bonded material. A final
wash with 15 column volumes of 1PBS was applied
until the eluate showed no absorbance at 280 nm. The
bound material was eluted using three ml of 0.1M glycine-
HCl buffer (pH 3.5) and immediately neutralized with
0.5mL of 1M Tris-HCl (pH 7.5). This eluate was concen-
trated to a final volume of 200mL with Amicon Ultra 5 kDa
molecular weight cutoff centrifugal filter devices (Millipore,
Billerica, MA). The buffer exchange was completed in these
filters with 10mM Tris-HCl (pH 7.5). Protein concentra-
tions between 100 and 200 mg/mL were determined by
micro BCA protein assay (Pierce, Rockford, IL) and 20mL
aliquots were stored at 801C for further use. The specificity
of the interaction between CICs and ProceptorTM-
conjugated resin, and nonspecific interaction between
serum proteins and uncoupled resin, was confirmed by
denaturing SDS-PAGE analysis and silver staining
(Supporting Information Figs. 1 and 2). Moreover, serial
analysis of multiple individual serum samples by Procep-
torTM ELISA substantiated the minimal loss of CICs by
precipitation during sample preparation or storage (data not
shown).
2.3 2-DE
2-DE was performed at 201C with a Bio-Rad Protean IEF Cell
system, a Criterion gel rig and associated power supply, 11 cm
IPG Ready Strips (pH 3–10 linear), 10% bis-tris Criterion XT
precast gels, and reagents according to the manufacturer’s
guidelines (Bio-Rad Laboratories, Hercules, CA). Briefly, a
CIC concentration of 10mg was made up to a total volume of
185mL in sample rehydration buffer (8M urea, 2M thiourea,
2% CHAPS, 2% SB3-10, 20mM DTT, 2% b-octylglucoside,
40mM Tris, 0.2% Bio-Lyte 3/10 ampholyte, and 0.001%
bromophenol blue). Each sample was applied to a linear pH
3–10 IPG strip and passively rehydrated for 16 h at room
temperature prior to IEF, in accordance with manufacturer’s
recommendations. The first dimension separation of proteins
by IEF was performed in duplicate (n5 2). A total of 30000
Vh were applied during IEF. After IEF, the strips were
removed, rinsed in excess 18.2MO H2O, and equilibrated in
2mL of buffer containing 6M urea, 0.375M Tris-HCl buffer
(pH 8.8), 2% SDS, 20% glycerol, and 2% (w/v) DTT for
15min with continuous shaking. After the first incubation,
the IEF strips were incubated for another 15min, with
continuous shaking, at room temperature in a similar buffer,
substituting 2.5% (w/v) iodoacetamide for 2% (w/v) DTT.
Postequilibration, IPG strips were laid into single well 10%
bis-tris Criterion gels and sealed in with 0.5% agarose (w/v).
Five microliter of broad range SDS-PAGE molecular weight
standards (Bio-Rad Laboratories) were used per gel. The
second dimension separation was achieved with denaturing
SDS-PAGE run at 175V for 1.5h. Following 2-DE, gels were
stained overnight with Sypro Ruby (Molecular Probes,
Eugene, OR) according to manufacturer’s recommendations.
2.4 Image and statistical analysis
Protein spots were visualized using GelPix (Genetix, New
Milton, UK). Gels were scanned as 16-bit gray scale Tif image
files and protein spot analysis was performed with Progenesis
Samespots version 2.0 build 2644.18003 software (Nonlinear
Dynamics, Newcastle upon Tyne, UK) comprising gel warp-
ing, normalization, and comparison modules. Briefly, a single
reference gel was assigned as the gel image with the most
clearly resolved spots detected and all remaining gel images
were aligned to this reference. The same spot outlines were
overlaid onto all images, ensuring no data was omitted at this
early stage. Landmark spots were used to confirm spot
matching across all gels and three-dimensional ‘‘peaks’’ were
used to verify spot assignment. The protein spots in each
image were automatically linked between the individual gel
images for each patient. The Samespots software performs
log transformation of the spot volume ratios to generate
normally distributed data. Log normalized volume was used
in quantifying differential expression. Intrasample variance of
spot volumes within each group was accounted for and
outlying values were not included in this study.
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Matched and volumes normalized within replicate sample
sets were used to create ‘‘master’’ gels for each patient or
group, from the series of CIC samples. Subsequent qualita-
tive subtraction of one patient group ‘‘master’’ gel from
another revealed a population of proteins uniquely expressed
in the CICs of that particular patient group. Qualitative
differential spot analysis was performed on ‘‘master’’ gels
from two combined groups (combined disease group versus
combined MR/healthy group). Pairwise comparisons were
made to establish patient group–patient group variations.
Within the Samespots review module, each comparison was
filtered to find the spots (i) with a significant difference in
their expression pattern (pr0.05 for the unpaired T-test) and
(ii) having a two-fold or greater change in protein spot
expression between the two groups. Fold change was calcu-
lated as the ratio of the average log normalized volume
between the two groups. Results from an independent
sample T-test (SPSS v.15, Chicago, IL) for comparisons of
individual spot volumes between groups prior to log
normalization are listed in Supporting Information Table 1.
2.5 Cluster analysis
Quantitative data sets were analyzed using Epclust (http://
www.bioinf.ebc.ee/EP/EP/EPCLUST/), a generic data cluster-
ing, visualization, and analysis tool for genomic or proteomic
expression data. Hierarchal cluster analysis allows samples with
interindividual protein expression patterns that are highly
similar to be reordered in an agglomerative fashion, using the
unweighted pair-group method with arithmetic mean clustering
procedure. In this method, the distance between two clusters is
calculated as the average distance between all pairs of objects in
the two different clusters. Euclidean distance was the similarity
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Figure 1. Isolation of the
aggressive JIA CIC proteome.
Representative 2-DE reveals
455 protein spots per gel (pH
range 5–9) for CICs of JIA
patients with an aggressive
phenotype. Representative 2-DE
of CICs from MR and healthy
groups are shown in Support-
ing Information Fig. 1. HSA,
human serum albumin.
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measure used to group or separate the expression data. The
grouping of protein expression levels is presented in the form of
heat map accompanied by dendrograms with trees and bran-
ches depicting the extent of similarity between the different
groups in the samples.
2.6 Protein spot extraction and identification
Protein spots were excised using Gelpix (Genetix) and
subjected to in-gel trypsin digestion and the eluted peptides
were subjected to nanoflow HPLC-MS/MS analysis using an
ABI quadrupole time-of-flight (QSTAR XL) MS/MS system
(Applied Biosystems, Foster City, CA), as previously
described [41, 42]. Peptide identifications were achieved
using the IPI human (67 524 entries, July 8, 2007) [43] and
NCBI nonredundant (NCBInr) databases (5 222 402 entries,
July 2, 2007) with the Mascot 2.0 search engine (Matrix
Science, Boston, MA). The constraints used were (i) tryptic
peptides with up to one missed cleavage site and (ii) 0.3Da
mass tolerances for both MS and MS/MS fragment ions.
The charge states of precursor ions selected were 1–3.
Oxidation of methionine and N-terminal deamidation were
specified as variable modifications and carbamidomethyla-
tion of cysteine as a fixed modification, respectively.
Unambiguous identification was judged by the criteria
reported previously [42].
3 Results
3.1 Establishment of a JIA CIC proteome
As compared to the magnitude of the human plasma proteome
(http://ca.expasy.org/swiss-2dpage/map5plasma_human), we
have demonstrated a preliminary method to establish a refined
CIC proteome for JIA patients with an aggressive phenotype.
Results of 2-DE from the CE, EOA, MR, and healthy groups
revealed that the majority of proteins from CICs migrated
within the pH 5–9 range (Fig. 1; MR and healthy are shown in
Supporting Information Fig. 1). Using comparative analysis of
results from the National Biomedical Research Foundation
(NBRF) protein database, we established the presence of IgM
and IgG heavy chains, k and l light chains, and HSA. These
identities were previously confirmed by MALDI-TOF analysis of
protein spots from systemic lupus erythematosus (SLE) CIC
2-DE gels [41]. We determined intra- and intersample variability
in protein concentration by analyzing changes in spot intensity
over replicate 2-DE gels, per sample. Visual inspection of repli-
cate sets indicated that protein spot coordinates (pI/MW) and
intensities were similar between gels run from the same
sample, but significant differences were noted between patient’s
and, more importantly, between groups.
Initially, 1019 ‘‘spots’’ were detected with 1.1-fold or
more difference between gels. After further review of spot
quality, software recognition algorithm resulted in spot
editing that increased the net number of detected spots to
1150 ‘‘spots’’. From here, approximately 455 true protein
spots were retained for comparison across individuals and
patient groups. The remaining 695 ‘‘spots’’ were rejected
because of nonspot features such as being elongated and
having poor resolution. A threshold of two-fold or greater
difference between protein expression patterns was set to
further filter out less significant spots. Normalized spot
volume comparisons of groups CE, EOA, and MR to healthy
controls revealed interesting trends in protein expression
patterns (Supporting Information Fig. 2). When comparing
the CE group to healthy controls, 61 proteins showed two-
fold or greater increased levels while 58 proteins showed a
Figure 2. Normalized spot
volume comparisons of the
CE/EOA combined disease
group to MR/healthy
combined control group.
Samespots analysis reveals
37 protein spots with in-
creased expression (gray)
and 45 protein spots with
decreased expression (black)
in the CICs of the CE/EOA
combined disease group
as compared with MR/
healthy combined control
group. Differential expres-
sion patterns are two-fold
or greater and significant,
pr0.05, for the unpaired
T-test.
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Figure 3. Putative disease-
associated proteins high-
lighted in regions A–D.
Protein spots within regions
A–D from Fig. 2 were picked
and analyzed by nanoflow
HPLC-MS/MS. CE, chronic,
erosive; EOA, early onset,
aggressive; MR, medical
remission.
Individual CIC 
- +
10 Exponential Scale 
Euclidean Distance 
Figure 4. Hierarchal cluster
analysis reveals trends in
disease-associated protein ex-
pression. Quantitative data sets
showing fold differences in
protein expression were analy-
zed using Epclust. Subsequent
hierarchal cluster analysis
allows samples with inter-
individual protein expression
patterns that are highly similar
to be reordered into clusters of
similarity. The list of differen-
tially expressed proteins was
generated using a cut-off of
two-fold or greater expression
difference and T-test with
pr0.05. Euclidean distance is
the measure of similarity
between two clusters, calcu-
lated as the average distance
between all pairs of objects in
the two different clusters. Indi-
vidual protein spots are labeled
on the vertical axis. Patient’s
individual CIC proteomes are
labeled on the horizontal axis of
the heat map: CE, A1-3; EOA,
B1-5; MR C1-6, and Healthy,
D1-4. The e10 scale represents
varying degrees of increased
protein and decreased protein
expression.
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two-fold or greater decrease in expression (Supporting
Information Fig. 2A). Moreover, the EOA group displayed
77 proteins with two-fold or greater expression while 63
proteins had two-fold or greater decrease as compared to
healthy controls (Supporting Information 2B). Finally, when
comparing the protein expression profiles of the MR and
healthy groups, the MR group had 43 proteins with a two-
fold or greater increase in spot intensity and 21 proteins
with a two-fold or greater decrease (Supporting Information
Fig. 2C).
Table 2. Identification and quantification of disease-associated proteins
Spot ID Protein ID MOWSE
score
Peptides
matched
Accession pI MW
(kDa)
Fold change in CE and
EOA disease
Marker Glycogen phosphorylase b 467 16 gi231300 6.6 95.8 N/A
Region A
23 Not identified 6.9 57.6 4.5
39 IGHM protein 182 14 IPI00479708 6.9 69.3 3.1
43/46 Ig mu heavy chain disease
protein
88/139 6/6 IPI00385264 5.1 43.5 2.9/3.0
44 IGHM protein 233 9 IPI00477090 5.9 68.1 2.9
218/244 SERPINA1 a-1-antitrypsin
precursor
139/206 7/6 IPI00553177 5.4 46.9 3.5/3.1
229 ALB uncharacterized protein
ALB
70 5 IPI00022434 6.3 73.8 2.9
276 TF serotransferrin precursor 183 7 IPI00022463 6.8 79.3 2.7
311 ALB isoform 1 of serum
albumin precursor
61 10 IPI00745872 5.9 71.3 2.6
Region B
165/176 Not identified 3.7/4 64.5/72.1 4.6/3.2
194/211 Not identified 3.5/3.3 68.7/61.5 2.9/3.2
247/309 Not identified 3.4/3.2 47.8/44.6 3.1/2.5
Region C
144/174 Glyceraldehyde-3-phosphate
dehydrogenase
139/181 6/7 IPI00219018 8.6 36.2 3.5/3.2
203/230 Glyceraldehyde-3-phosphate
dehydrogenase
106/119 7/8 IPI00219018 8.6 36.2 2.9/2.4
240 IGHG2 Putative unchara-
cterized protein
87 7 IPI00399007 7.6 46.7 2.7
DKFZp686I04196 (fragment)
268 Ig g-2 chain C region
(fragment)
58 5 IPI00399007 7.7 36.5 2.3
295 ALB uncharacterized protein
ALB
61 1 IPI00022434 6.3 73.8 2.1
Region D
22 IGKV1-5 protein 117 5 IPI00430820 5.7 26 4.2
32 Putative uncharacterized
protein
64 3 IPI00785200 7.6 25.4 3.8
34 IGL@ protein 70 2 IPI00154742 5.9 25.1 3.7
41 Not identified 6.1 24.7 3.2
50 Ig k chain V-I region WEA 91 1 IPI00003469 9.1 11.9 2.8
58/215 IGKV1-5 protein 171/171 3/3 IPI00419424 6.3 26.5 2.9/3.4
63 Ig k chain V-II region MIL 67 1 IPI00387110 9.4 12.2 3.0
136 Putative uncharacterized
protein
64 3 IPI00785200 7.6 25.4 5.3
249 Ig k chain V-IV region Len 72 1 IPI00387120 7.9 12.7 3.2
277 Ig k chain V-I region EU 49 1 IPI00387026 8.6 11.9 3.4
285 IGKC protein 48 4 IPI00430808 6.2 25.9 2.9
286 IGLV4-3 41 2 IPI00382938 6.3 26.3 2.4
Spot trypsin digests were identified using nanoflow HPLC-MS/MS, correlated to compiled peptide data (Matrix Science), with a high
degree of confidence (pr0.05). Glycogen phosphorylase b was a positive control spot picked from the 2-DE molecular weight marker.
Proteomics Clin. Appl. 2009, 3, 829–840 835
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
3.2 Expression of disease-associated proteins in
CICs
To characterize potential disease-associated proteins within
the CICs of CE and EOA groups, the protein expression data
from these two groups were combined to identify common
spots that are subsequently absent in the combined MR and
healthy control group. A series of 37 potential disease-
associated CIC proteins were expressed at a two-fold or
higher level than could be detected in CICs from the MR
and healthy combined control group (Fig. 2). The majority
of these putative disease-associated proteins were located
within four distinct regions, as defined by similar mobility/
charge (Fig. 3). Alternatively, 45 proteins had a two-fold or
greater decrease in their intensity levels as compared with
the MR and healthy combined control group. Hierarchal
cluster analysis confirmed potential disease-associated
proteins by identifying highly similar inter-individual
protein expression patterns (Fig. 4). Resulting heat maps
and dendrograms revealed interesting trends of increased
protein expression that were common to the combined
disease group and decreased or absent in the combined
control group. Proteins with a statistically significant
(pr0.05) increase in their expression and their identities are
listed in Table 2.
Twenty-eight of the 37 potential disease-associated
proteins, with sufficient yields from trypsin digests, were
identified by nanoflow HPLC-MS/MS, followed by search-
ing the IPI human and NCBInr databases with a high
degree of confidence (pr0.05). The proteins spots were
numbered by the image analysis software and shown in
Figs. 2 and 3. The majority of these proteins characterized
as Ig heavy and light chains. Spots 229, 295, and 311 were
identified as isoforms of serum albumin. Spots 276 and
218/244 were identified as serotransferrin precursor and
alpha-1-antitrypsin (a-1AT) precursor with 2.7- and 3.5/3.1-
fold increased expression, respectively. Spot 144, 174, 203,
and 230 were identified as isoforms of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) with 3.5-, 3.2-, 2.9-, and
2.4-fold increased expression, respectively. Spot 32 and 136
were identified as putative uncharacterized proteins with
3.8- and 5.3-fold overexpression, respectively. Additionally,
spot 240 was identified as an uncharacterized IgG heavy
chain protein with a 2.7-fold increased expression. Spot 224
was excluded from this analysis as the protein concentration
was insufficient.
4 Discussion
As previously stated, JIA is a heterogenous group of diseases
with variable clinical presentations and long-term physical
outcomes. Laboratory markers are limited and usually
derived from peripheral whole blood. Dysregulation of
immune function is a hallmark of the disease, involving
altered humoral, cell-mediated, and innate responses. In
light of this, a role for pathogenic CICs has been established
[3, 8–17]. In many IC-mediated diseases either the offending
antigen is unknown or multiple candidate antigens have
been implicated. Identifying disease-associated proteins in
CICs, or related posttranslational modifications, could have
potential diagnostic utility by recognizing aggressive disease
early in its course and providing an important window for
therapeutic intervention.
Several putative disease markers have been identified in
the SF of chronic adult RA and spondyloarthropathy,
including: calgranulins A, B, and C, fibrinogen b-chain,
fructose bisphosphate aldolase A, and a-enolase [29]. Addi-
tionally, serum amyloid A was found to be increased in both
the serum and SF of adult RA patients. Other disease
markers, including C-reactive protein and haptoglobin have
been correlated with a chronic inflammatory adult RA
[29, 44, 45]. However, few studies have been done to identify
proteins associated with disease in JIA [28, 46–48]. Recently,
Gibson et al. [28] identified collagen X and T-cell receptor ab
fragments at significantly higher levels within SF of patients
suffering from recurrent episodes of inflammation. Like-
wise, Rosenkranz et al. [48] characterized protein expression
in the SF of the three most common subtypes of JIA.
Among the proteins identified with differential expression
patterns were precursors for a-1-antichymotrypsin, and
serotransferrin, and Igk chain C. Some findings presented
in the present work, including a-1AT, serotransferrin, and
Igk chain C, are homologous to these proteins.
The proteins that comprise CICs are ideal targets as
elevated levels of CICs represent a pathologic overflow and
parallel activity of the arthritis and systemic features [9, 18,
49–52]. Modern proteomic technologies, such as 2-DE
combined with MS, afford the ability to efficiently char-
acterize protein profiles within CICs. One of the proteins
identified in this study, GAPDH, is a classic metabolic
enzyme involved in glycolysis and energy production.
However, numerous studies established that it is a multi-
functional protein involved in DNA processing, apoptosis,
and transferrin transport [53, 54]. Cytosolic GAPDH has a pI
of 7.0–7.5, whereas nuclear GAPDH has a pI of 8.7 [53].
Thus, posttranslational modifications (i.e. phosphorylation)
may be involved in the multiple functions of GAPDH.
Moreover, oxidative stress induces nitric oxide-mediated
S-nitrosylation of GAPDH and its subsequent nuclear
translocation to mediate tumor necrosis factor (TNF)-related
apoptosis inducing ligand-induced cell death [55]. Interest-
ingly, TNF-related apoptosis inducing ligand has been
implicated in the proliferation of synovial fibroblasts that
contribute to the joint pathology seen in adult RA [56].
Of particular relevance to this study, the antigenicity of
GAPDH and its role as a potential autoantigen has been
investigated [57]. GAPDH has been implicated as a
component of the proliferating cell nuclear antigen (PCNA)
in SLE. Specifically, a 37 kDa protein (pI 8.5) component of
the PCNA complex reacted with antibodies from SLE sera
and was identified as GAPDH. Serum PCNA levels, which
836 J. M. Low et al. Proteomics Clin. Appl. 2009, 3, 829–840
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
may be crucial for antigen presentation, are significantly
elevated in SLE patients who are positive for these anti-
bodies. Importantly, PCNA complexes are released into
peripheral blood with other nuclear antigen whenever acti-
vated cells are killed by apoptosis. Other work has identified
anti-GAPDH antibodies in diseases such as multiple
sclerosis and glaucoma, which is believed to have an auto-
immune component [58, 59]. Further study has shown
significantly increased copies of GAPDH DNA in the serum
and plasma of RA patients indicative of increased cell
death [60].
Interestingly, a number of glycolytic enzymes have been
implicated in adult RA, related spondyloarthropathies, and
the corresponding K/BxN murine arthritis model. As
previously mentioned, fructose bisphosphate aldolase A and
a-enolase were shown to be overexpressed in the inflamed
synovium of patients with spondyloarthropathy [29].
Previous studies have confirmed antibodies reactive to either
of these glycolytic enzymes in the sera of patient’s adult RA
[61–63]. Likewise, autoantibodies targeting triosephosphate
isomerase have also been identified in RA serum and SF,
albeit at lower sensitivities [29]. In the K/BxN murine model
of RA, glucose-6-phosphate isomerase (GPI)-anti-GPI
immune complexes are necessary for and integral to disease
pathophysiology [64, 65]. While inconclusive, anti-GPI
antibodies have also been identified in the sera and SF of
patients with adult RA, and to a lesser degree in JIA [66–69].
Some studies link the presence of these antibodies to
disease with an aggressive phenotype or extra-articular
manifestations. In our patient cohort, expression of GAPDH
was up to 3.5-fold higher in CICs of the combined disease
group as compared with the combined control group. With a
pI of 8.6, the identified protein is most likely nuclear
GAPDH. Taken together, these findings suggest that
GAPDH should be considered a disease-associated protein
of interest. Additional analysis of GAPDH within CICs may
shed light on a potential mechanism in autoimmune
responses.
In addition to GAPDH, a precursor to serotransferrin
was also significantly overexpressed in the CICs of the
combined disease group. Most extracellular Fe21 in the
plasma is bound to transferrin. Immune cells require Fe21
for activation, proliferation, and maturation [70]. Likewise,
Fe21 is essential for the production of highly toxic hydroxyl
radicals that mediate macrophage-mediated cytoxicity. Of
potential importance, GAPDH has recently been shown to
function as a novel transferrin receptor on macrophages
[54]. These new findings suggest that the interaction
between GAPDH and transferrin might determine how they
are associated with the disease process. Other studies have
confirmed an upregulation of serum transferrin and ferritin
in active JIA disease [71–74]. Taken together, these findings
suggest that the interaction of Fe21-bound transferrin with
GAPDH could reveal cryptic epitopes in both transferrin
and GAPDH. Furthermore, the enhanced transport of Fe21
by both GAPDH and natural resistance-associated macro-
phage protein 1 could directly contribute to the pathogenesis
that leads to joint destruction.
In addition to transferrin, serum a-1AT has been linked to
active JIA [73]. As an acute-phase protein, a-1AT is a serine
protease inhibitor with a variety of functions. A relevant
function to this study regards a-1AT as an anti-inflammatory
molecule and regulator of the immune response. Key
features include the inhibition of antibody-dependent cell-
mediated cytotoxicity, and the cytoxicity mediated by T cells,
natural killer cells, neutrophils, and monocytes [75, 76].
Regulation of innate immunity is also attributed to a-1AT. By
controlling CD14 expression, a-1AT inhibits lipopoly-
saccharide-induced proinflammatory cytokines TNF-a, inter-
leukin-1b, and interleukin-8 [77]. Another study has shown a
role for a-1AT in the inhibition of two key molecules involved
in joint destruction, matrix metalloproteinase, and TNF-a
[78]. Subsequently, a lack of a-1AT in adult RA correlates with
more tissue destruction [79–81]. In this study, a-1AT
precursor was expressed up to 3.5-fold greater levels in CICs
from the combined disease group as compared with the
combined control group. Further work is required to deter-
mine the role of a-1AT as a disease-associated protein and
what could transpire due to its presence in CICs.
Of the remaining identified proteins, three uncharacterized
proteins were overexpressed 2.7-, 3.8-, and 5.3-fold, respec-
tively. Likewise, a number of immunoglobulin heavy and light
chains were overexpressed up to 4.2-fold in CICs from the
disease group. The increased expression of immunoglobulin
in the disease groups, as compared with the MR and healthy
controls, is not surprising as there is increased B cell activity
that is paramount to the disease process. This activity results in
an overproduction of disease-associated immunoglobulin, or
autoantibodies, that contribute to CIC formation. The varying
mobility observed among the light chains, in particular, would
suggest a number of potential posttranslational modifications
such as the addition of sugar moieties. Further analysis is
required to determine potential posttranslational modifications
or other characteristics of these proteins that associate them
with the disease process in JIA. While five of the identified
proteins had only one peptide matched, their MS/MS spectra
were confident and they did share sequence homology with
other proteins identified within this study. In light of these
relationships, further analysis is required to establish the
importance of these proteins. Protein spots 23, 165, 176, 194,
211, 247, and 309 had insufficient protein yields to be defini-
tively identified. The protein loading and sensitivity of the 2-DE
technique need to be improved. To the best of our knowledge,
this is the first study to characterize the CIC proteome from
patients with JIA. These findings suggest a set of disease-
associated proteins linked to a destructive disease course.
Peptide profiles could be used to differentiate disease
subgroups to predict patients who are more likely to suffer
from severe disease. Moreover, ‘‘proteome records’’ from
patient CICs showing disease-associated changes over time
may allow tracking and refinement of therapeutic responses in
a given individual [29]. These ‘‘records’’ may serve as sentinels
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of joint damage, which can occur in patients suffering an
insidious disease. Additional analysis of these proteins should
give insight into the multifaceted mechanisms that contribute
to the etiology or maintenance of the disease process seen in
aggressive forms of JIA.
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